Physician profile
Lauren Louise Hansen
NPI 1275875205
$262,906.55
in general payments reported to CMS, 2019-2025
19 companies · $131K in 2025
The $131K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $729 · 2022: $1,623 · 2023: $75K · 2024: $54K · 2025: $131K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $198K · Travel and Lodging: $56K · Food and Beverage: $7,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $197,615.00 |
| Travel and Lodging | $55,601.29 |
| Food and Beverage | $7,337.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $229,113.11 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $30,265.40 | 2022-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $885.57 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $800.36 | 2021-2023 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $476.08 | 2021-2023 | Spravato |
| Neurocrine Biosciences, INC. | $292.86 | 2021-2022 | |
| Alkermes, INC. | $265.17 | 2021-2023 | Lybalvi |
| Axsome Therapeutics, INC. | $235.32 | 2023 | Auvelity |
| Corium, LLC | $133.43 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $129.54 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $116.35 | 2024 | Cobenfy |
| Lundbeck LLC | $53.86 | 2022-2023 | Rexulti |
| Noven Therapeutics, LLC | $35.95 | 2021 | |
| Tempus Ai, INC | $20.86 | 2024 | |
| Tersera Therapeutics LLC | $19.90 | 2025 | Zoladex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $17.93 | 2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $16.21 | 2022 | |
| Eisai INC. | $15.30 | 2021 | |
| Millicent US INC | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.